Mark Damian Hoffman
· Associate Professor of MedicineUniversity of Chicago · Dermatology and Molecular Sciences
Active 1992–2023
About
Mark Damian Hoffman, MD, is an Associate Professor of Medicine in the Department of Medicine at The University of Chicago. His clinical interests encompass a wide range of dermatological conditions including acne, autoimmune and connective tissue skin diseases, basal cell carcinoma, contact dermatitis, cutaneous lupus, vasculitis, dermatomyositis, hidradenitis suppurativa, skin infections, inpatient consultative dermatology, lichen planus, mole surveillance, occupational dermatitis, psoriasis, pyoderma gangrenosum, rosacea, sun damage screening, seborrheic keratosis, squamous cell carcinoma, and telangiectasia. Dr. Hoffman’s research and clinical work focus on complex dermatological conditions, including refractory dermatomyositis responsive to anifrolumab, metastatic Crohn's disease responsive to ustekinumab dose intensification, and novel eruptions related to immune checkpoint blockade. His contributions include case reports and studies on autoimmune skin diseases, autoinflammatory conditions, and the effects of various therapies on skin pathology. He maintains active engagement in research, as evidenced by his publications in reputable journals, and is dedicated to advancing understanding and treatment of dermatological diseases.
Research topics
- Medicine
- Internal medicine
- Dermatology
- Pathology
- Nuclear medicine
- Radiology
- Immunology
- Surgery
- Oncology
Selected publications
Refractory dermatomyositis responsive to anifrolumab
JAAD Case Reports · 2023 · 33 citations
Senior authorCorresponding- Medicine
- Dermatology
Dermatomyositis (DM) is a connective tissue disorder with dermatologic and/or extracutaneous manifestations. Although DM primarily affects skin and muscle, the disease can cause pathologic changes to other organs such as the lungs, and may be associated with malignancy. Various treatments are deployed in DM management, but their effects are inconsistent. Skin disease can be refractory to therapy, even when other involved organ systems are responsive.1 Interferons (IFNs) are believed to play a role in driving DM disease activity, and medications targeting IFN pathways are both available and under development.
2023-03-31
preprintOpen access<p>Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events among patients remaining on study for at least 3 months. Table S4 shows the proportion of patients receiving stereotactic body radiation therapy to all RECIST target lesions and all clinically or radiographically apparent metastases by response category.</p>
2023-03-31
preprintOpen access<p>Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events among patients remaining on study for at least 3 months. Table S4 shows the proportion of patients receiving stereotactic body radiation therapy to all RECIST target lesions and all clinically or radiographically apparent metastases by response category.</p>
2023-03-31
preprintOpen access<div>AbstractPurpose:<p>CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab (CSF1R inhibitor).</p>Patients and Methods:<p>This phase I clinical trial enrolled patients with advanced solid tumors that had progressed on standard therapies. SBRT was delivered to 1–4 metastases with nivolumab+urelumab or nivolumab+cabiralizumab given concurrently and following SBRT. Dose-limiting toxicity (DLT) was the primary endpoint with anatomic location-specific SBRT doses deemed safe if ≤33% DLT frequency was observed. Secondary endpoints included RECISTv1.1 response, progression-free survival (PFS), overall survival (OS), and molecular correlative studies.</p>Results:<p>Sixty patients were enrolled, and median follow-up for living patients is 13.8 months. Of these, 23 (38%) received SBRT+nivolumab+urelumab and 37 (62%) received SBRT+nivolumab+cabiralizumab. Seven patients (12%) experienced a DLT (<i>n</i> = 3 grade 3, <i>n</i> = 4 grade 4) in the following anatomic cohorts: abdominal/pelvic (3/17, 18%), liver (1/13, 8%), central lung (2/14, 14%), and peripheral lung (1/12, 8%). Of 41 patients radiographically evaluable for best overall response including 55 radiated and 23 unirradiated RECIST target lesions, 2 had complete responses (5%), 7 had partial responses (17%), 12 had stable disease (29%), and 20 had progression (49%). Median estimated PFS and OS are 3.0 months [95% confidence interval (CI), 2.9–4.8] and 17.0 months (95% CI, 6.8–undetermined), respectively. No patients with elevated pre-SBRT serum IL8 experienced a response.</p>Conclusions:<p>SBRT to ≤4 sites with nivolumab+urelumab or nivolumab+cabiralizumab for treating advanced solid tumors is feasible with acceptable toxicity and modest antitumor activity.</p><p><i>See related commentary by Rodriguez-Ruiz et al., p. 5443</i></p></div>
2023-03-31
preprintOpen access<div>AbstractPurpose:<p>CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab (CSF1R inhibitor).</p>Patients and Methods:<p>This phase I clinical trial enrolled patients with advanced solid tumors that had progressed on standard therapies. SBRT was delivered to 1–4 metastases with nivolumab+urelumab or nivolumab+cabiralizumab given concurrently and following SBRT. Dose-limiting toxicity (DLT) was the primary endpoint with anatomic location-specific SBRT doses deemed safe if ≤33% DLT frequency was observed. Secondary endpoints included RECISTv1.1 response, progression-free survival (PFS), overall survival (OS), and molecular correlative studies.</p>Results:<p>Sixty patients were enrolled, and median follow-up for living patients is 13.8 months. Of these, 23 (38%) received SBRT+nivolumab+urelumab and 37 (62%) received SBRT+nivolumab+cabiralizumab. Seven patients (12%) experienced a DLT (<i>n</i> = 3 grade 3, <i>n</i> = 4 grade 4) in the following anatomic cohorts: abdominal/pelvic (3/17, 18%), liver (1/13, 8%), central lung (2/14, 14%), and peripheral lung (1/12, 8%). Of 41 patients radiographically evaluable for best overall response including 55 radiated and 23 unirradiated RECIST target lesions, 2 had complete responses (5%), 7 had partial responses (17%), 12 had stable disease (29%), and 20 had progression (49%). Median estimated PFS and OS are 3.0 months [95% confidence interval (CI), 2.9–4.8] and 17.0 months (95% CI, 6.8–undetermined), respectively. No patients with elevated pre-SBRT serum IL8 experienced a response.</p>Conclusions:<p>SBRT to ≤4 sites with nivolumab+urelumab or nivolumab+cabiralizumab for treating advanced solid tumors is feasible with acceptable toxicity and modest antitumor activity.</p><p><i>See related commentary by Rodriguez-Ruiz et al., p. 5443</i></p></div>
Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
JAAD Case Reports · 2022-12-05 · 5 citations
articleOpen accessSenior authorSKIN The Journal of Cutaneous Medicine · 2022-03-04
articleOpen accessCemiplimab is the first PD-1 inhibitor approved in the United States for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), but not melanoma. We describe a case of amelanotic melanoma (AM) developing in a patient on cemiplimab therapy for invasive SCC. Cutaneous AM is a rare subtype of cutaneous melanoma that shows little or no melanin pigmentation on clinical and histological examination thus often leading to a high misdiagnosis rate. Physicians should consider atypical presentations of melanoma, including amelanotic melanoma, during surveillance of patients managed with immune checkpoint inhibitor therapy.
JAMA Dermatology · 2021-06-30 · 2 citations
letterOpen accessSenior authorCorrespondingThis case series observes 5 patients treated with nivolumab and cabiralizumab with stereotactic radiotherapy who developed punctate, atrophic depressions with histologic findings of elastolysis.
Clinical Cancer Research · 2021 · 42 citations
- Medicine
- Internal medicine
- Oncology
PURPOSE: CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab (CSF1R inhibitor). PATIENTS AND METHODS: This phase I clinical trial enrolled patients with advanced solid tumors that had progressed on standard therapies. SBRT was delivered to 1-4 metastases with nivolumab+urelumab or nivolumab+cabiralizumab given concurrently and following SBRT. Dose-limiting toxicity (DLT) was the primary endpoint with anatomic location-specific SBRT doses deemed safe if ≤33% DLT frequency was observed. Secondary endpoints included RECISTv1.1 response, progression-free survival (PFS), overall survival (OS), and molecular correlative studies. RESULTS: = 4 grade 4) in the following anatomic cohorts: abdominal/pelvic (3/17, 18%), liver (1/13, 8%), central lung (2/14, 14%), and peripheral lung (1/12, 8%). Of 41 patients radiographically evaluable for best overall response including 55 radiated and 23 unirradiated RECIST target lesions, 2 had complete responses (5%), 7 had partial responses (17%), 12 had stable disease (29%), and 20 had progression (49%). Median estimated PFS and OS are 3.0 months [95% confidence interval (CI), 2.9-4.8] and 17.0 months (95% CI, 6.8-undetermined), respectively. No patients with elevated pre-SBRT serum IL8 experienced a response. CONCLUSIONS: .
Case Reports in Dermatology · 2021 · 3 citations
Senior authorCorresponding- Medicine
- Dermatology
- Pathology
Dermatomyositis (DM) and its variant, clinically amyopathic DM, are widely recognized entities. DM sine dermatitis, a variant without skin involvement, is less widely reported. DM with neither muscle nor skin manifestations has not been reported. We herein describe the first account of a patient with a myositis-specific antibody presenting with an array of clinical findings in the absence of both muscle and pathognomonic skin disease. This case report details the multidisciplinary assessment of an anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive individual with inflammatory polyarthropathy, mucocutaneous capillary changes, and evidence of interstitial lung disease but lacking overt skin and muscle disease. This presentation is paradoxically but appositely deemed to represent a unique form of DM, which may be best described as "amyopathic hypodermatitic dermatomyositis." Early recognition and documentation of these cases will help to characterize this variant in the future, determine its frequency, and guide management.
Frequent coauthors
- 6 shared
Theodore Karrison
University of Chicago
- 6 shared
Chih‐Yi Liao
University of Chicago
- 5 shared
Olwen Hahn
University of Chicago
- 5 shared
Corey C. Foster
- 5 shared
Gini F. Fleming
- 5 shared
Rita Nanda
University of Chicago
- 5 shared
Steven J. Chmura
University of Chicago
- 5 shared
Peter H. O’Donnell
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Mark Damian Hoffman
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup